Latest News

Drug Development - Cancer Immunology and Immunotherapy - Head and Neck Cancers - Non-Small-Cell Lung Cancer, Metastatic - Melanoma and other Skin Tumours - Pancreatic Cancer

Novel Strategies Tested To Boost Checkpoint Inhibitor Efficacy

  • 20 Apr 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Investigators explore whether combining pembrolizumab with a TLR9 agonist or durvalumab with an IDO1 inhibitor are feasible approaches for the treatment of solid tumours...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Novel Strategies Tested To Boost Checkpoint Inhibitor Efficacy

Cancer Aetiology, Epidemiology, Prevention - Colon Cancer

Following Nutritional, Physical Activity Guidelines May Aid Colon Cancer Survival

  • 13 Apr 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Colon cancer survivors who adhere to healthy living guidelines may have better survival than peers who do not follow diet and physical activity recommendation

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Following Nutritional, Physical Activity Guidelines May Aid Colon Cancer Survival

Drug Development - Cancer Immunology and Immunotherapy - Non-Small-Cell Lung Cancer, Metastatic

IL-15 Superagonist Plus Nivolumab Tested For Metastatic NSCLC

  • 11 Apr 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Early results suggest that outpatients with metastatic non-small-cell lung cancer were able to tolerate a combination of nivolumab and the interleukin-15 superagonist ALT-803

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof IL-15 Superagonist Plus Nivolumab Tested For Metastatic NSCLC

Breast Cancer, Early Stage - Breast Cancer, Locally Advanced - Cancer Aetiology, Epidemiology, Prevention

Sarcopenia, Adiposity Predict Nonmetastatic Breast Cancer Mortality

  • 10 Apr 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Assessing a patient’s muscle and adipose tissue mass may help evaluate their risk of dying from nonmetastatic breast cancer

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Sarcopenia, Adiposity Predict Nonmetastatic Breast Cancer Mortality

Anti-Cancer Agents & Biologic Therapy - Hepatobiliary Cancers - Translational Research

METIV-HCC Results Cast Doubt On Validity Of MET Inhibition In Advanced HCC

  • 06 Apr 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Treatment with the MET inhibitor tivantinib in the second line does not improve survival over placebo in patients with MET-high advanced hepatocellular carcinoma

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof METIV-HCC Results Cast Doubt On Validity Of MET Inhibition In Advanced HCC

Leukaemia - Personalised Medicine - Translational Research

Molecular Minimal Residual Disease Linked To AML Relapse, Survival

  • 05 Apr 2018
  • Author : By Shreeya Nanda, Senior medwireNews Reporter

Persistent mutations in genes associated with haematological malignancies are a prognostic factor for acute myeloid leukaemia patients who are in complete remission

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Molecular Minimal Residual Disease Linked To AML Relapse, Survival

Anti-Cancer Agents & Biologic Therapy - Colon Cancer

Trial Collaboration Gives IDEA Of Optimal Adjuvant Chemotherapy Duration For Stage III Colon Cancer

  • 03 Apr 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Choice of chemotherapy regimen and risk status could help guide clinicians considering 3-month and 6-month adjuvant strategies for stage III colon cancer

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Trial Collaboration Gives IDEA Of Optimal Adjuvant Chemotherapy Duration For Stage III Colon Cancer

Anti-Cancer Agents & Biologic Therapy - Gastric Cancer - Translational Research

Gastric Cancer Gene Classifier May Predict Adjuvant Chemotherapy Benefit

  • 28 Mar 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Gene expression biomarkers might guide the use of adjuvant chemotherapy in patients with stage II–III gastric cancer...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Gastric Cancer Gene Classifier May Predict Adjuvant Chemotherapy Benefit

Anti-Cancer Agents & Biologic Therapy - Rectal Cancer - Surgery and/or Radiotherapy of Cancer

Short-Term Results Add To Evidence For Total Neoadjuvant Strategy In Locally Advanced Rectal Cancer

  • 27 Mar 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Total neoadjuvant therapy may result in a greater adherence to chemotherapy and a higher response rate for patients with locally advanced rectal cancer than an adjuvant approach...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Short-Term Results Add To Evidence For Total Neoadjuvant Strategy In Locally Advanced Rectal Cancer

Anti-Cancer Agents & Biologic Therapy - Cancer Immunology and Immunotherapy - Renal Cell Cancer

First-Line Nivolumab Plus Ipilimumab Supported For Intermediate-, Poor-Risk Advanced RCC

  • 26 Mar 2018

Patients with previously untreated intermediate- or poor-risk renal cell carcinoma experienced better outcomes with nivolumab plus ipilimumab than with sunitinib...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof First-Line Nivolumab Plus Ipilimumab Supported For Intermediate-, Poor-Risk Advanced RCC

Cancer Aetiology, Epidemiology, Prevention - Gastric Cancer

H. pylori Eradication Combats Metachronous Gastric Cancer

  • 23 Mar 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Patients with early gastric cancer who receive antibiotic treatment for Helicobacter pylori infection have a reduced risk of metachronous disease...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof H. pylori Eradication Combats Metachronous Gastric Cancer

Cancer Immunology and Immunotherapy - Gastric Cancer

KEYNOTE-059 Points To Potential For Pembrolizumab Role In Advanced Gastric Cancer

  • 22 Mar 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Pembrolizumab monotherapy is well tolerated and shows efficacy for patients with advanced, previously treated gastric or gastro-oesophageal junction cancer

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof KEYNOTE-059 Points To Potential For Pembrolizumab Role In Advanced Gastric Cancer

Anti-Cancer Agents & Biologic Therapy - Colon Cancer - Rectal Cancer

Modified XELIRI May Offer FOLFIRI Alternative For Metastatic CRC Regimens

  • 21 Mar 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Capecitabine plus irinotecan may be noninferior to FOLFIRI chemotherapy for second-line treatment of metastatic colorectal cancer with or without use of bevacizumab...

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Modified XELIRI May Offer FOLFIRI Alternative For Metastatic CRC Regimens

Neuroendocrine Cancers

Gastroenteropancreatic NETs Show Late Recurrence Patterns

  • 20 Mar 2018
  • Author : By Lynda Williams, Senior medwireNews Reporter

Follow-up imaging for gastroenteropancreatic neuroendocrine tumours could be optimised to match later patterns of recurrence

ESMO Members: your membership includes full access to OncologyPRO Daily News, created exclusively for you by medwireNews. Sign in now to access this page.

view detailsof Gastroenteropancreatic NETs Show Late Recurrence Patterns

Drug Development - Cancer Immunology and Immunotherapy

TAT 2018: Looking At the Future of Intra Tumoral Immunotherapy

  • 16 Mar 2018

Aurelien Marabelle explains that intratumoural immunotherapy considers immunostimulatory products delivered directly into the tumour in order to initiate or stimulate an immune response in situ, at the tumour site. With the recent revolution of immunotherapy, many biotechs and pharma companies are interested to develop immunostimulatory products to be injected locally into the tumour with two aims: to have more potent immunostimulatory drugs and less toxicity for patients.

view detailsof TAT 2018: Looking At the Future of Intra Tumoral Immunotherapy